Abstract
Atrophy in multiple brain regions has been reported in the early stages of Parkinson’s Disease, but there have been few longitudinal studies. How intrinsic properties of the brain, such as anatomical connectivity, local cell type distribution and gene expression combine to determine the pattern of disease progression remains unknown. One hypothesis proposes that the disease stems from prion-like propagation of misfolded alpha-synuclein via the connectome that might cause varying degrees of tissue damage based on local properties.
Here we used MRI data from the Parkinson Progression Markers Initiative to test this model by mapping the progression of brain atrophy over one, two and four years and relating it to brain structural and functional connectivity, cell type expression and gene ontology enrichment analyses. In this longitudinal study, we derived atrophy progression maps for the three time points using deformation-based morphometry applied to T1-weighted MRI from 74 de novo Parkinson’s Disease patients (50 Men: 24 Women) and 157 healthy control participants (115 Men: 42 Women). After regressing out the expected age and sex effects associated with normal aging, we found that atrophy significantly progressed over two and four years in the caudate, nucleus accumbens, hippocampus, and the temporal, parietal, occipital and posterior cingulate cortex. This progression was shaped by both structural and functional brain connectivity. Also, the progression of atrophy was more pronounced in regions with a higher expression of genes related to synapses and was related to the prevalence of oligodendrocytes and endothelial cells.
In sum, we demonstrate that the progression of atrophy in Parkinson’s Disease is in line with the prion-like propagation hypothesis of alpha-synuclein and provide evidence that synapses may be especially vulnerable to synucleinopathy. In addition to identifying vulnerable brain regions, this study reveals different factors that may be implicated in the neurotoxic mechanisms leading to progression in Parkinson’s Disease.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was funded by grants from the Michael J Fox Foundation for Parkinson's Research, the Alzheimer's Association, the Weston Brain Institute, the Canadian Institutes of Health Research and the Healthy Brains for Healthy Lives (HBHL) initiative of McGill University. SR receives a scholarship from the Fonds de Recherche du Quebec – Sante.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All the data used in this study were obtained from the Parkinson's progression markers initiative (PPMI), an open access database (www.ppmi-info.org/data).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
MRI data used in this article are available for download at www.ppmi-info.org/data. All other datasets and software used are available from the sources cited in the Methods. The DBM atrophy progression maps will be made available on request.
Abbreviations
- AHBA
- Allen Human Brain Atlas
- BBB
- blood-brain barrier
- Bl
- Baseline
- CAT12
- Computational Anatomy Toolbox
- DBM
- deformation-based morphometry
- FC
- functional connectivity
- FDR
- false discovery rate
- FEW
- Family-wise error
- GDS
- Geriatric Depression Scale
- GO
- gene ontology
- GOrilla
- Gene Ontology enRIchment anaLysis and visuaLizAtion tool
- HC
- healthy control
- HVLT
- Hopkins Verbal Learning Test
- L-Dopa
- Levodopa
- MDS-UPDRS
- Movement Disorder Society Unified Parkinson Disease Rating Scale
- MNI
- Montreal Neurological Institute
- MoCA
- Montreal Cognitive Assessment
- NFL
- neurofilament light polypeptide
- PPMI
- Parkinson’s progression markers initiative
- pTFCE
- probabilistic approach for threshold-free cluster enhancement
- SD
- Standard Deviation
- SPM12
- Statistical Parametric Mapping software
- STAI
- State-Trait Anxiety Inventory
